Academic Journal
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study
| العنوان: | Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study |
|---|---|
| المؤلفون: | Pentheroudakis, George, Briassoulis, E. Ch, Kalofonos, H. P., Fountzilas, George, Economopoulos, T., Samelis, G., Koutras, A. K., Karina, M., Xiros, N., Samantas, E., Bamias, A. T., Pavlidis, Nicholas |
| المساهمون: | Pavlidis, Nicholas 0000-0002-2195-9961, Pentheroudakis, George 0000-0002-6632-2462, Kalofonos, H. P. 0000-0002-3286-778X |
| المصدر: | Acta Oncologica |
| سنة النشر: | 2008 |
| المجموعة: | University of Cyprus: Gnosis Institutional Repository / Ιδρυματικό αποθετήριο Πανεπιστημίου Κύπρου "Γνῶσις" |
| مصطلحات موضوعية: | Greece, Article, Human, Neoplasms, Palliative care, Humans, Adult, Aged, Controlled study, Female, Middle aged, Cancer survival, Carboplatin, Disease progression, Paclitaxel, Predictive value of tests, Priority journal, Alopecia, Anemia, Antineoplastic combined chemotherapy protocols, Clinical article, Clinical trial, Diarrhea, Disease-free survival, Drug efficacy, Drug safety, Fatigue, Febrile neutropenia, Multicenter study, Myalgia |
| الوصف: | Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer of unknown primary (CUP). Patients and methods. Eligible CUP patients with adenocarcinoma or poorly differentiated carcinoma, performance status of 0-2, adequate organ function and assessable disease were treated with docetaxel 75 mg/m2 and carboplatin at an area under the concentration time-curve (AUC) of 5, both as 30-minute intravenous infusions, every three weeks. Patients with isolated axillary adenopathy, squamous cell cervical or inguinal adenopathy and PSA or germ-cell serum tumour markers were excluded. Results. Forty-seven patients entered the trial, 24 with predominantly nodal disease or non-mucinous peritoneal carcinomatosis (favourable risk) and 23 with visceral metastases (unfavourable risk). A median of 6 cycles of chemotherapy were administered, with relative dose intensities of both drugs >90%. Response rates were 32% (46% in favourable risk, 17% in unfavourable), comparable to the activity of paclitaxel/platinum regimes, though complete remissions were seen only in favourable risk patients. Granulocyte-colony stimulating factor support was used in a third of treatment cycles. Toxicity was mild and manageable, with grade 3-4 neutropenia in 26% of patients, febrile neutropenia in 7% and severe non-hematologic side-effects in less than 8% of patients. No toxic deaths or severe neurotoxicity were seen. Median time to progression (TTP) and overall survival (OS) were 5.5 and 16.2 months respectively. Survival was driven mainly by favourable-risk patients (22.6 months), as those with visceral metastases had a poor median survival of only 5.3 months. Good performance status and low-volume disease predicted for superior outcome, while docetaxel relative dose-intensity was a positive prognosticator only in favourable-risk patients. Conclusions. One-hour docetaxel/carboplatin is a ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://gnosis.library.ucy.ac.cy/handle/7/42331 |
| DOI: | 10.1080/02841860701843043 |
| الاتاحة: | https://gnosis.library.ucy.ac.cy/handle/7/42331 https://doi.org/10.1080/02841860701843043 |
| رقم الانضمام: | edsbas.5790E523 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1080/02841860701843043 |
|---|